



VEGA BIOIMAGING

Vega Bioimaging Technologies Inc.

Vision

To enable precision medicine in cancer through precise biopsy characterization.

Mission

To provide novel immunolabelling that allows the application of quantitativity and multiplexing in histopathology for more accurate diagnostics.

Core Technology



Multiplexed nanoparticle-based immunolabelling (US10.239.122) allows for unprecedented sensitivity and protein quantitation.

Compatible with standard FFPE samples and H&E routine!

Vega Bioimaging provides more reliable and sensitive companion diagnostic tests for anti-cancer drugs.



Pharmaceutical firms get reproducible testing for therapy eligibility



Pathologists save time and get a better portrait of the patient



Patients receive a tailored treatment in a timely manner

vegabioimaging.com

PROTEIN QUANTITATION >>
FOR MORE ACCURATE DIAGNOSTICS

Opening new possibilities for researchers and clinical users.

Leadership



Cécile Darvot
Co-Founder & CEO



Michel Meunier
Co-Founder



Sergiy Patskovsky
Co-Founder

Vega Bioimaging

Montreal, QC, Canada

cecile@vegabioimaging.com

vegabioimaging.com